Brief: Zymeworks Announces Decision To Discontinue Clinical Development Of Zw171, A Mesothelin-Directed T Cell Engager
02/09/2025 11:42
Zymeworks Inc ZYME.O: ZYMEWORKS ANNOUNCES DECISION TO DISCONTINUE CLINICAL DEVELOPMENT OF ZW171, A MESOTHELIN-DIRECTED T CELL ENGAGER ZYMEWORKS INC - PREPARING AN IND FILING FOR ZW209, OUR DLL3-DIRECTED TRISPECIFIC T CELL ENGAGER, PLANNED IN FIRST HALF OF 2026 ZYMEWORKS INC - FURTHER DOSE EVALUATION UNLIKELY TO SUPPORT PROFILE Source text: ID:nGNX4rkYR3 Further company coverage: ZYME.O
Recent news on Zymeworks
See all newsUS STOCKS ON THE MOVE-Huron Consulting, RingCentral, Selective Insurance
U.S. STOCKS ON THE MOVE-Huron Consulting, Crown Castle, Bloom Energy
US STOCKS ON THE MOVE-Booz Allen Hamilton, SLB, Deckers Outdoor
US STOCKS ON THE MOVE-American Express, Gorman-Rupp, Moderna
Zymeworks gains on up to $813 million Roche licensing deal for lung cancer drug